Sol-Millennium marketed modified syringes and needles without required FDA clearance and had quality-system and reporting violations.
What happened
FDA inspected Sol-Millennium Medical, Inc. in Chicago, Illinois, from December 14 through December 20, 2023. FDA found the firm marketed syringe configurations—such as syringes with needles, luer slip or eccentric tips, low-dead-space claims, and accessories—that were not covered by its K101359 clearance and lacked required FDA clearance or approval. The letter also cites registration and listing failures, missing design-change records, complaint-handling failures including a needle embedded in a patient, and deficient or late medical device reporting.
What FDA found
The firm marketed syringe configurations with different needles, tips, low-dead-space claims, and accessories without FDA clearance or approval for those changes.
Section 501(f)(1)(B) and 502(o) of the Act; 21 U.S.C. §§ 351(f)(1)(B), 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)(i)-(ii)The firm did not complete annual registration and device listing for fiscal year 2024 and did not register or list its Chicago, Lugano, and Shanghai facilities.
Section 510 of the Act, 21 U.S.C. § 360; 21 CFR 807.20(a) and 807.40(a)The firm shipped devices labeled with former Lawrenceville and Suwanee, Georgia addresses that were neither the manufacturing location nor the principal place of business.
Section 502(b) of the Act, 21 U.S.C. § 352(b); 21 CFR 801.1(e)The firm lacked documented design-change control for combining syringes with needles and adding needle sizes to insulin and TB syringes.
21 CFR 820.30(i)The firm did not open a complaint file for a report of a needle embedded in a patient and did not evaluate confirmed cracked-syringe complaints for medical device reporting.
21 CFR 820.198(a)The firm's MDR procedure was deficient and it failed to submit a 30-day report for a needle-breakage complaint that reasonably suggested a serious injury risk.
21 CFR 803.17 and 803.50(a)(2)
What FDA wants
FDA asks Sol-Millennium to correct the cited violations and provide supporting documentation, including completed corrective actions, testing for new 510(k) submissions, and updated complaint and MDR records. The excerpt provided does not state a response deadline.
Who should pay attention
- hospitals and clinics using Sol-Millennium syringes and needles
- distributors and importers of these devices
- contract manufacturers and specification developers for syringe devices
This is a summary. Read the original letter on fda.gov.